WHIM syndrome: from mechanism to targeted therapy – advances shaping clinical care
Increased awareness, opportunities for screening at birth, improved pathological and genetic diagnostics, and 2024 FDA approval of the first oral CXCR4 antagonist create practical advance in targeting WHIM syndrome. As a CID with lifetime risk for humoral deficiency, impaired antiviral defense and malignancy, WHIM warrants long-term monitoring and further investigation into broader applications of CXCR4 antagonism.
Authors
- Jolán E. Walter (ORCID: https://orcid.org/0000-0002-6192-0703)
- João P. Pereira (ORCID: https://orcid.org/0000-0002-5694-4938)
- Christoph B. Geier (ORCID: https://orcid.org/0000-0003-4353-8663)
- Jacob R. Bledsoe (ORCID: https://orcid.org/0000-0002-2387-5462)
- Rahim Miller
Institutions
- Boston Children's Hospital (US)
- Carl von Ossietzky Universität Oldenburg (DE)
- Harvard University (US)
- Johns Hopkins University (US)
- Yale University (US)
- Johns Hopkins All Children's Hospital (US)
- Klinikum Oldenburg (DE)
Publication Details
- Journal
- Current Opinion in Allergy and Clinical Immunology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1097/aci.0000000000001128
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00